Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma.

World Journal of Gastroenterology : WJG
Kazuhiro KasaiKazuyuki Suzuki

Abstract

To evaluate the efficacy of transcatheter arterial chemoembolization (TACE) using a suspension of a fine-powder formulation of cisplatin (DDPH) for hepatocellular carcinoma (HCC). The study population was comprised of 164 patients who were treated by TACE alone. Of these patients, 76 underwent TACE using a suspension of DDPH in lipiodol (LPD) (DDPH group), and the remaining 88 underwent TACE with an emulsion of doxorubicin (ADM) with LPD (ADM group). We compared the DDPH group with the ADM group in terms of the objective early response rate, progression free survival (PFS) and overall survival (OS). The objective early response rate in the DDPH group was significantly higher than that in the ADM group (54% vs 24%, P < 0.001). The PFS rate in the DDPH group was also significantly higher than that in the ADM group (P < 0.001). Moreover, the OS in the DDPH group was significantly longer than that in the ADM group (P = 0.002). Although the incidence rate of nausea or vomiting in the DDPH group was higher than that in the ADM group, the ADM group showed a higher incidence rate of the adverse events of hepatic arterial damage and leucopenia. No other serious complications were observed in either group. We conclude that TACE using a s...Continue Reading

References

May 1, 1990·AJR. American Journal of Roentgenology·S ShiinaA Terano
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·K TakayasuH Hasegawa
Jul 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T KanematsuK Sugimachi
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Mar 11, 1999·The New England Journal of Medicine·H B El-Serag, A C Mason
Feb 5, 2000·Cardiovascular and Interventional Radiology·K YamamotoI Narabayashi
Apr 29, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C La VecchiaF Levi
May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chung-Mau LoJohn Wong
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farin KamangarWilliam F Anderson
Aug 8, 2006·Gastroenterology·Kenichi TakayasuUNKNOWN Liver Cancer Study Group of Japan
Jun 7, 2008·Cardiovascular and Interventional Radiology·Kengo MorimotoKimihiko Kichikawa

❮ Previous
Next ❯

Citations

Apr 23, 2013·TheScientificWorldJournal·Satoru MurataShin-ichiro Kumita
Jul 6, 2013·Japanese Journal of Radiology·Yuki TomozawaKiyoshi Murata
Oct 12, 2013·World Journal of Gastroenterology : WJG·Toru Ishikawa
Jan 22, 2013·Liver International : Official Journal of the International Association for the Study of the Liver·Joong-Won ParkAnn-Lii Cheng
Jun 15, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Masatoshi KudoKiwamu Okita
Oct 12, 2018·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Kenji Ikeda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.